JP2024545233A5 - - Google Patents
Info
- Publication number
- JP2024545233A5 JP2024545233A5 JP2024535725A JP2024535725A JP2024545233A5 JP 2024545233 A5 JP2024545233 A5 JP 2024545233A5 JP 2024535725 A JP2024535725 A JP 2024535725A JP 2024535725 A JP2024535725 A JP 2024535725A JP 2024545233 A5 JP2024545233 A5 JP 2024545233A5
- Authority
- JP
- Japan
- Prior art keywords
- structural formula
- compound represented
- prodrug
- compound
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111544686 | 2021-12-16 | ||
| CN202111544686.7 | 2021-12-16 | ||
| PCT/CN2022/139765 WO2023109965A1 (zh) | 2021-12-16 | 2022-12-16 | 一种喜树碱类化合物及其偶联物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545233A JP2024545233A (ja) | 2024-12-05 |
| JP2024545233A5 true JP2024545233A5 (enExample) | 2025-12-24 |
Family
ID=86774914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535725A Pending JP2024545233A (ja) | 2021-12-16 | 2022-12-16 | カンプトテシン化合物及びそのコンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250059201A1 (enExample) |
| EP (1) | EP4450506A4 (enExample) |
| JP (1) | JP2024545233A (enExample) |
| KR (1) | KR20240120744A (enExample) |
| CN (2) | CN118414339A (enExample) |
| AU (1) | AU2022408887A1 (enExample) |
| CA (1) | CA3241157A1 (enExample) |
| MX (1) | MX2024007498A (enExample) |
| WO (1) | WO2023109965A1 (enExample) |
| ZA (1) | ZA202405368B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| KR20250049568A (ko) * | 2022-07-15 | 2025-04-11 | 페온 테라퓨틱스 리미티드 | Cdcp1에 결합하는 항체 약물 접합체 및 이의 용도 |
| WO2024097812A1 (en) * | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
| WO2024193682A1 (en) * | 2023-03-23 | 2024-09-26 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-tpbg/met antibodies and uses thereof |
| EP4721767A1 (en) * | 2023-06-05 | 2026-04-08 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. | Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3 |
| KR20260089547A (ko) * | 2023-10-10 | 2026-06-15 | 상하이 이노브콩 파마슈티컬 테크놀로지 코., 엘티디 | 새로운 i형 토포이소머라아제 억제제 및 그 제조 방법과 용도 |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| CN122374343A (zh) | 2023-11-30 | 2026-07-10 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途 |
| AU2024415931A1 (en) | 2023-12-27 | 2026-07-16 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Multi-specific antibody targeting her3 and trop2 and conjugate thereof |
| WO2025140662A1 (en) * | 2023-12-29 | 2025-07-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-egfr/her3 antibodies and uses thereof |
| WO2025149019A1 (en) * | 2024-01-12 | 2025-07-17 | Shanghai Ruotuo Biosciences Co., Ltd. | Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications |
| TW202539743A (zh) * | 2024-02-07 | 2025-10-16 | 大陸商長春金賽藥業有限責任公司 | 帶有連接系統的抗體藥物偶聯物 |
| WO2025191470A1 (en) * | 2024-03-12 | 2025-09-18 | Astrazeneca Ab | Processes and compounds for the preparation of topoisomerase i inhibitor linker-payloads |
| WO2025256632A1 (zh) * | 2024-06-14 | 2025-12-18 | 长春金赛药业有限责任公司 | 靶向b7-h3和psma的双特异性抗体及抗体-药物偶联物 |
| WO2025261469A1 (zh) * | 2024-06-20 | 2025-12-26 | 科霸生物（江苏）有限公司 | 喜树碱衍生物、抗体、药物偶联物、及其组合物和应用 |
| CN122297712A (zh) * | 2024-12-27 | 2026-06-30 | 杭州中美华东制药有限公司 | 一类喜树碱缀合物的制备方法 |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2026162789A1 (en) * | 2025-01-31 | 2026-08-06 | BioNTech SE | Linkers for antibody drug conjugates |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) * | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| US6136978A (en) * | 1993-06-30 | 2000-10-24 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| GB9512670D0 (en) * | 1995-06-21 | 1995-08-23 | Sod Conseils Rech Applic | Camptothecin analogues |
| US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US7067666B2 (en) * | 2003-06-27 | 2006-06-27 | Research Triangle Institute | 7-substituted camptothecin and camptothecin analogs and methods for producing the same |
| DE102005009099A1 (de) * | 2005-02-28 | 2006-08-31 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Camptothecin-Peptid-Derivate und diese enthaltende Arzneimittel |
| US10195288B2 (en) * | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| CN107753954A (zh) | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| SG11201603960XA (en) | 2014-01-31 | 2016-07-28 | Daiichi Sankyo Co Ltd | Anti-her2 antibody-drug conjugate |
| TWI871999B (zh) | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| US11384104B2 (en) * | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
| CN106349233B (zh) | 2015-07-15 | 2021-06-01 | 上海翰森生物医药科技有限公司 | 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用 |
| EP3546448B1 (en) | 2016-11-25 | 2022-04-06 | Mabwell (Shanghai) Bioscience Co., Ltd. | Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof |
| CN108101825B (zh) * | 2016-11-25 | 2022-02-22 | 迈威(上海)生物科技股份有限公司 | 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途 |
| UA130338C2 (uk) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| KR20240104214A (ko) * | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| US20230097908A1 (en) * | 2020-01-22 | 2023-03-30 | Medimmune Limited | Compounds and conjugates thereof |
| TW202140076A (zh) | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| KR20240031235A (ko) * | 2021-05-27 | 2024-03-07 | 자임워크스 비씨 인코포레이티드 | 캄프토테신 유사체, 접합체 및 사용 방법 |
-
2022
- 2022-12-16 CN CN202280083630.2A patent/CN118414339A/zh active Pending
- 2022-12-16 JP JP2024535725A patent/JP2024545233A/ja active Pending
- 2022-12-16 EP EP22906709.5A patent/EP4450506A4/en active Pending
- 2022-12-16 KR KR1020247023132A patent/KR20240120744A/ko active Pending
- 2022-12-16 CA CA3241157A patent/CA3241157A1/en active Pending
- 2022-12-16 MX MX2024007498A patent/MX2024007498A/es unknown
- 2022-12-16 AU AU2022408887A patent/AU2022408887A1/en active Pending
- 2022-12-16 CN CN202211627164.8A patent/CN116813631A/zh active Pending
- 2022-12-16 US US18/720,569 patent/US20250059201A1/en active Pending
- 2022-12-16 WO PCT/CN2022/139765 patent/WO2023109965A1/zh not_active Ceased
-
2024
- 2024-07-10 ZA ZA2024/05368A patent/ZA202405368B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535598A5 (enExample) | ||
| JP2022537158A5 (enExample) | ||
| RU2586885C2 (ru) | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство | |
| JP6743015B2 (ja) | Ｋｓｐ阻害剤の脱グリコシル化抗ｔｗｅａｋｒ抗体との抗体薬物複合体（ａｄｃ類） | |
| EP4523704A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| JP2022512057A (ja) | 抗体薬物複合体のためのリンカーおよびその使用 | |
| JP2020525513A (ja) | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 | |
| KR102374788B1 (ko) | 아르기나제 저해제 및 이의 치료적 용도 | |
| EP4185328A1 (en) | Antibody-conjugated chemical inducers of degradation of brm and methods thereof | |
| EP3313524A1 (de) | Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-cd123-antikörpern | |
| JP2018524313A (ja) | キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体 | |
| JP2025513163A (ja) | 抗体－薬物コンジュゲート、その医薬組成物及びその使用 | |
| JP2025516873A (ja) | タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用 | |
| JP2025148380A (ja) | 抗体－薬物コンジュゲート及びそれらの使用 | |
| JP2024523422A (ja) | 抗腫瘍化合物およびその応用 | |
| JP2023553808A5 (enExample) | ||
| TWI775203B (zh) | 製備環縮肽之方法 | |
| WO2024235134A9 (zh) | 具有靶向作用的偶联物及其制备方法和用途 | |
| JPWO2020166592A1 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| JP2021525265A5 (enExample) | ||
| CN120957755A (zh) | 多环类药物偶联物及其制备方法和用途 | |
| JP2026502000A (ja) | 抗ｂｄｃａ２抗体－薬物コンジュゲートおよびその使用 | |
| JP2024501453A5 (enExample) | ||
| CN120957754A (zh) | 稠环化合物及其制备方法和用途 | |
| WO2021013693A1 (en) | Antibody drug conjugates (adcs) with nampt inhibitors |